Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study

Naghmeh Abbasi Kasbi; F. Ghadiri; M. A. Sahraian; M. A. Nahayati; A. Naser Moghadasi; H. Ghalyanchi Langroodi; M. Poursadeghfard; S. Hosseini; H. Heidari; S. M. Baghbanian; H. Kamali; Z. Ameli; S. Shahmohammadi; S. Navardi